Cargando…
The hazard of fondaparinux in non-critically ill patients with COVID-19: Retrospective controlled study versus enoxaparin
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497738/ https://www.ncbi.nlm.nih.gov/pubmed/33007739 http://dx.doi.org/10.1016/j.thromres.2020.09.024 |
| _version_ | 1783583378837078016 |
|---|---|
| author | Prandoni, Paolo Cattelan, Anna Maria Carrozzi, Laura Leone, Lucia Filippi, Lucia De Gaudenzi, Egidio Villalta, Sabina Pesavento, Raffaele |
| author_facet | Prandoni, Paolo Cattelan, Anna Maria Carrozzi, Laura Leone, Lucia Filippi, Lucia De Gaudenzi, Egidio Villalta, Sabina Pesavento, Raffaele |
| author_sort | Prandoni, Paolo |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7497738 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-74977382020-09-18 The hazard of fondaparinux in non-critically ill patients with COVID-19: Retrospective controlled study versus enoxaparin Prandoni, Paolo Cattelan, Anna Maria Carrozzi, Laura Leone, Lucia Filippi, Lucia De Gaudenzi, Egidio Villalta, Sabina Pesavento, Raffaele Thromb Res Letter to the Editors-in-Chief Elsevier Ltd. 2020-12 2020-09-17 /pmc/articles/PMC7497738/ /pubmed/33007739 http://dx.doi.org/10.1016/j.thromres.2020.09.024 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editors-in-Chief Prandoni, Paolo Cattelan, Anna Maria Carrozzi, Laura Leone, Lucia Filippi, Lucia De Gaudenzi, Egidio Villalta, Sabina Pesavento, Raffaele The hazard of fondaparinux in non-critically ill patients with COVID-19: Retrospective controlled study versus enoxaparin |
| title | The hazard of fondaparinux in non-critically ill patients with COVID-19: Retrospective controlled study versus enoxaparin |
| title_full | The hazard of fondaparinux in non-critically ill patients with COVID-19: Retrospective controlled study versus enoxaparin |
| title_fullStr | The hazard of fondaparinux in non-critically ill patients with COVID-19: Retrospective controlled study versus enoxaparin |
| title_full_unstemmed | The hazard of fondaparinux in non-critically ill patients with COVID-19: Retrospective controlled study versus enoxaparin |
| title_short | The hazard of fondaparinux in non-critically ill patients with COVID-19: Retrospective controlled study versus enoxaparin |
| title_sort | hazard of fondaparinux in non-critically ill patients with covid-19: retrospective controlled study versus enoxaparin |
| topic | Letter to the Editors-in-Chief |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497738/ https://www.ncbi.nlm.nih.gov/pubmed/33007739 http://dx.doi.org/10.1016/j.thromres.2020.09.024 |
| work_keys_str_mv | AT prandonipaolo thehazardoffondaparinuxinnoncriticallyillpatientswithcovid19retrospectivecontrolledstudyversusenoxaparin AT cattelanannamaria thehazardoffondaparinuxinnoncriticallyillpatientswithcovid19retrospectivecontrolledstudyversusenoxaparin AT carrozzilaura thehazardoffondaparinuxinnoncriticallyillpatientswithcovid19retrospectivecontrolledstudyversusenoxaparin AT leonelucia thehazardoffondaparinuxinnoncriticallyillpatientswithcovid19retrospectivecontrolledstudyversusenoxaparin AT filippilucia thehazardoffondaparinuxinnoncriticallyillpatientswithcovid19retrospectivecontrolledstudyversusenoxaparin AT degaudenziegidio thehazardoffondaparinuxinnoncriticallyillpatientswithcovid19retrospectivecontrolledstudyversusenoxaparin AT villaltasabina thehazardoffondaparinuxinnoncriticallyillpatientswithcovid19retrospectivecontrolledstudyversusenoxaparin AT pesaventoraffaele thehazardoffondaparinuxinnoncriticallyillpatientswithcovid19retrospectivecontrolledstudyversusenoxaparin AT thehazardoffondaparinuxinnoncriticallyillpatientswithcovid19retrospectivecontrolledstudyversusenoxaparin AT prandonipaolo hazardoffondaparinuxinnoncriticallyillpatientswithcovid19retrospectivecontrolledstudyversusenoxaparin AT cattelanannamaria hazardoffondaparinuxinnoncriticallyillpatientswithcovid19retrospectivecontrolledstudyversusenoxaparin AT carrozzilaura hazardoffondaparinuxinnoncriticallyillpatientswithcovid19retrospectivecontrolledstudyversusenoxaparin AT leonelucia hazardoffondaparinuxinnoncriticallyillpatientswithcovid19retrospectivecontrolledstudyversusenoxaparin AT filippilucia hazardoffondaparinuxinnoncriticallyillpatientswithcovid19retrospectivecontrolledstudyversusenoxaparin AT degaudenziegidio hazardoffondaparinuxinnoncriticallyillpatientswithcovid19retrospectivecontrolledstudyversusenoxaparin AT villaltasabina hazardoffondaparinuxinnoncriticallyillpatientswithcovid19retrospectivecontrolledstudyversusenoxaparin AT pesaventoraffaele hazardoffondaparinuxinnoncriticallyillpatientswithcovid19retrospectivecontrolledstudyversusenoxaparin AT hazardoffondaparinuxinnoncriticallyillpatientswithcovid19retrospectivecontrolledstudyversusenoxaparin |